Bafna Pharmaceuticals Ltd vs Mercury Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 135.7 as of 30 Apr 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Mercury Laboratories Ltd changed from 14.4 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 16.80% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Mercury Laboratories Ltd changed from ₹ 77.11 crore on March 2021 to ₹ 98.29 crore on March 2025 . This represents a CAGR of 4.97% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The revenue of Mercury Laboratories Ltd for the Dec '25 is ₹ 18.66 crore as compare to the Sep '25 revenue of ₹ 19.8 crore. This represent the decline of -5.76% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The ebitda of Mercury Laboratories Ltd for the Dec '25 is ₹ 2.44 crore as compare to the Sep '25 ebitda of ₹ 2.92 crore. This represent the decline of -16.44% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Mercury Laboratories Ltd changed from ₹ 0.34 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of 85.24% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Mercury Laboratories Ltd changed from 7.87 % on March 2021 to 13.38 % on March 2025 . This represents a CAGR of 11.20% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Mercury Laboratories Ltd

Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
Subsequently, it converted into Private Limited Company & incorporated in February, 1982.
Later, it converted into Limited Company in 1992 in Maharashtra.
The Company has obtained ISO 9001:2008 registrations.
It is engaged into the manufacturing and export of wide range of Pharmaceutical items.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Mercury Laboratories Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Mercury Laboratories Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 321 Cr while Market cap of Mercury Laboratories Ltd is 90 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Mercury Laboratories Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Mercury Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Mercury Laboratories Ltd?

As of May 3, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹135.7. On the other hand, Mercury Laboratories Ltd stock price is INR ₹750.0.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Mercury Laboratories Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Mercury Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.